DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease
This is a multicenter, international, open-label, single-arm, multicohort, two-stage optimal Simon's design, phase II clinical trial
Advanced Breast Cancer|HER2-positive Breast Cancer|Brain Metastases|Leptomeningeal Metastasis
DRUG: Trastuzumab deruxtecan
Cohort 1, asses efficacy, defined as 16 weeks progression-free survival (PFS) of DS8201a, To assess efficacy -defined as 16 weeks progression-free survival (PFS)- per Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) and Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 of trastuzumab deruxtecan (DS-8201a) in patients with pretreated unresectable locally advanced or metastatic HER2-positive BC with non-progressing BM (after WBRT and/or SRS and or surgery). 16 weeks-PFS, defined as the period of time from treatment initiation to the first occurrence of disease progression or death from any cause, whichever occurs first during at least first 6 months. Progression will be determined locally by the investigator through the use of Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria for intracranial (IC) and Response Evaluation Criteria in Solid Tumors (RECIST) criteria v.1.1 for both extracranial lesions and overall (IC and extracranial) lesions., Baseline up to 16 weeks|Cohort 2, 3 and 4, asses efficacy defined as ORR-IC (DS-8201a), To assess efficacy -defined as intracranial overall response rate (ORR-IC) per RANO-BM of trastuzumab deruxtecan (DS-8201a) in patients with pretreated unresectable locally advanced or metastatic BC:

1. HER2-positive or HER2-low expressing with untreated BMs (Cohort 2);
2. HER2-positive with progressing BMs after local treatment (Cohort 3);
3. HER2-low expressing with progressing BMs after local treatment (Cohort 4).

ORR-IC, defined as a complete response (CR) or partial response (PR), and determined locally by the investigator through the use of RANO-BM criteria., From 16 weeks up tp 14 month|Cohort 5 asses efficacy,defined as OS of DS-8201a, To assess efficacy -defined as OS- of trastuzumab deruxtecan (DS-8201a) in patients with pretreated unresectable locally advanced or metastatic HER2-positive or HER2-low expressing BC with LMCOS defined as the time from treatment initiation to death from any cause. Patients without documented death at the time of the final analysis will be censored at the date of the last follow-up, From 16 weeks up tp 14 month
Cohort 1 to assess efficacy -defined as ORR, ORR, defined as a complete response (CR) or partial response (PR), determined locally by the investigator through the use of RANO-BM criteria for IC lesions and RECIST criteria v. 1.1 for both extracranial lesions and overall (IC and extracranial) lesions., From 16 weeks up tp 14 month|Cohort 1 to assess efficacy -defined as CBR, CBR, defined as an objective response (CR or PR), or stable disease (SD) for at least 24 weeks, determined locally by the investigator through the use of RANO-BM criteria for IC lesions and RECIST v.1.1 for both extracranial lesions and overall (IC and extracranial) lesions., From 16 weeks up tp 14 month|Cohort 1 to assess efficacy -defined as TTR, TTR, defined as the time from the treatment initiation to time of the first objective tumor response observed for patients who achieved a CR or PR, determined locally by the investigator through the use of RANO-BM criteria for IC lesions and RECIST v.1.1 for both extracranial lesions and overall (IC and extracranial) lesions., From 16 weeks up tp 14 month|Cohort 1 to assess efficacy -defined as DoR, DoR, defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first, determined locally by the investigator through the use of RANO-BM criteria for IC lesions and RECIST v.1.1 for both extracranial lesions and overall (IC and extracranial) lesions., From 16 weeks up to 14 months|Cohort 1 to assess efficacy -defined as OS, OS, defined as the time from treatment initiation to death from any cause. Patients without documented death at the time of the final analysis will be censored at the date of the last follow-up., From 16 weeks up to 14 months|Cohort 1: To assess efficacy -defined as PFS-, PFS, defined as the period of time from treatment initiation to the first occurrence of disease progression or death from any cause, whichever occurs first. Progression will be determined locally by the investigator through the use of RANO-BM criteria for IC lesions and RECIST criteria v.1.1 for both extracranial lesions and overall (IC and extracranial) lesions., Through study completion, an average of 1 year|Cohort 1: to assess efficacy -defined as best percentage of change, Best percentage of change from baseline in the size of CNS lesions, defined as the biggest decrease, or smallest increase if no decrease will be observed, and determined locally by the investigator through use of RANO-BM criteria., From 16 weeks up to 14 months|Cohort 1, To assess the safety and tolerability of trastuzumab deruxtecan (DS-8201a) in this population., Patient safety and adverse events (AEs) will be evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v.5.0. All AEs and serious adverse events (SAEs) will be assessed to determine the safety and tolerability of the treatment., From 16 weeks up to 14 months|Cohort 2, 3 and 4: To assess efficacy -defined as 6-month PFS, PFS, defined as the period of time from treatment initiation to the first occurrence of disease progression or death from any cause, whichever occurs first. Progression will be determined locally per RANO-BM criteria for IC lesions and RECIST criteria v.1.1 for both extracranial lesions and overall (IC and extracranial) lesions., From 16 weeks up to 14 months|Cohort 2, 3 and 4. To asses efficacy -defined as ORR, ORR, defined as a CR or PR, determined locally by the investigator through the use of RECIST criteria v.1.1 for both extracranial lesions and overall (IC and extracranial) lesions., From 16 weeks up to 14 months|Cohort 2, 3 and 4. To asses efficacy -defined as CBR, CBR, defined as an objective response (CR or PR), or SD for at least 24 weeks, determined locally by the investigator through the use of RECIST criteria v.1.1 for both extracranial lesions and overall (IC and extracranial) lesions., From 16 weeks up to 14 months|Cohort 2, 3 and 4. To asses efficacy -defined as TTR, TTR, defined as the time from the treatment initiation to time of the first objective tumor response (tumor shrinkage of â‰¥ 30%) observed for patients who achieved a CR or PR, determined locally by the investigator through the use of RECIST criteria v.1.1 for both extracranial lesions and overall (IC and extracranial) lesions., From 16 weeks up to 14 months|Cohort 2, 3 and 4. To asses efficacy -defined as DOR, DoR, defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first, determined locally by the investigator through the use of RECIST criteria v.1.1 for both extracranial lesions and overall (IC and extracranial) lesions., From 16 weeks up to 14 months|Cohort 2, 3 and 4. To asses efficacy -defined as OS, OS, defined as the time from treatment initiation to death from any cause. Patients without documented death at the time of the final analysis will be censored at the date of the last follow-up, From 16 weeks up to 14 months|Cohort 2, 3 and 4. To asses efficacy -defined as best percentage of change, Best percentage of change from baseline in the size of tumor lesions, defined as the biggest decrease, or smallest increase if no decrease will be observed, and determined locally by the investigator through the use of RANO-BM criteria for IC lesions and RECIST criteria v.1.1 for both extracranial lesions and overall (IC and extracranial) lesions., From 16 weeks up to 14 months|Cohort 2, . To asses efficacy -defined as time to WBR and/or SRS, Time to WBR and/or SRS (only for cohort 2), defined as the time from the treatment initiation to time of CNS disease progression that requires treatment with WBR and/or SRS, and determined locally by the investigator through the use of RANO-BM criteria and RECIST criteria., From 16 weeks up to 14 months|Cohort 2, 3 and 4.To assess the safety and tolerability of trastuzumab deruxtecan (DS-8201a), Patient safety and AEs will be evaluated using the NCI-CTCAE v.5.0. All AEs and SAEs will be assessed to determine the safety and tolerability of the treatment., From 16 weeks up to 14 months|Cohort5, To assess efficacy -defined as ORR, CNS ORR, defined as a CR or PR, determined locally by the investigator through the use of RANO-BM criteria for IC lesions and RECIST criteria v.1.1 for both extracranial lesions and overall (IC and extracranial) lesions., From 16 weeks up to 14 months|Cohort5, To assess efficacy -defined as PFS, PFS, defined as the period of time from treatment initiation to the first occurrence of disease progression or death from any cause, whichever occurs first. Progression will be determined locally by the investigator through the use of RANO-BM criteria for IC lesions and RECIST criteria v.1.1 for both extracranial lesions and overall (IC and extracranial) lesions., From 16 weeks up to 14 months|Cohort5, To assess efficacy -defined as CBR, CBR, defined as an objective response (CR or PR), or SD for at least 24 weeks, determined locally by the investigator through the use of RANO-BM criteria for IC lesions and RECIST criteria v.1.1 for both extracranial lesions and overall (IC and extracranial) lesions., From 16 weeks up to 14 months|Cohort5, To assess efficacy -defined as TTR, TTR, defined as the time from the treatment initiation to time of the first objective tumor response observed for patients who achieved a CR or PR, determined locally by the investigator through the use of RANO-BM criteria for IC lesions and RECIST criteria v.1.1 for both extracranial lesions and overall (IC and extracranial) lesions., From 16 weeks up to 14 months|Cohort5, To assess efficacy -defined as DOR, DoR, defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first, determined locally by the investigator through the use of RANO-BM criteria for IC lesions and RECIST criteria v.1.1 for both extracranial lesions and overall (IC and extracranial) lesions., From 16 weeks up to 14 months|Cohort5, To assess efficacy -defined as best percentage of change, Best percentage of change from baseline in the size of tumor lesions, defined as the biggest decrease, or smallest increase if no decrease will be observed, and determined locally by the investigator through the use of RANO-BM criteria for IC lesions and RECIST criteria v.1.1 for both extracranial lesions and overall (IC and extracranial) lesions, From 16 weeks up to 14 months|Cohort5, To assess the safety and tolerability of trastuzumab deruxtecan (DS-8201a) in this population., Patient safety and AEs will be evaluated using the NCI-CTCAE v.5.0. All AEs and SAEs will be assessed to determine the safety and tolerability of the treatment., From 16 weeks up to 14 months
To assess patient reported outcomes (PROs) using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-30) and its breast cancer module, QLQ-BR23 in this population., Overall change from baseline in patient-reported global health status/quality of life (GHS/QoL), functioning and symptoms; Time to deterioration in global QoL; Time to deterioration in pain; Time to next therapy., Baseline up to 18 months|To evaluate predictive or prognostic biomarkers (plasma and/or tissue and/or CSF) associated with disease activity status or response to treatment in this population., Relationship between tissue- and/or blood- and/or CSF-based biomarkers and patient clinical characteristics (e.g., baseline features) and outcome (e.g., duration of PFS)., Baseline up to 18 months|To identify possible mechanisms of resistance to study treatments through the comparative analysis of potential biomarkers from paired pre-treatment and post-progression tumor and/or blood and/or CSF samples from this population., Relationship between tissue- and/or blood- and/or CSF-based biomarkers and patient clinical characteristics (e.g., baseline features) and outcome (e.g., duration of PFS)., Baseline up to 18 months
Pretreated, unresectable locally advanced or metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-positive or HER2-low expressing breast cancer (BC) with untreated or treated brain metastases (BMs) or leptomeningeal carcinomatosis (LMC).